2025 Q4 -tulosraportti
Vain PDF
55 päivää sitten
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 365 | - | - | ||
| 85 | - | - | ||
| 5 000 | - | - | ||
| 10 000 | - | - | ||
| 46 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·13 min sittenThere is no one discussing economics in the Circio share? Here, circVec's results from the study programs are being discussed - 50-60X better effect in Eye, 40X in heart, x x in CNC, potential muscles, lungs, kidneys, low toxicity, specific delivery etc, partners etc. We are waiting for CAR-T shortly. Shares are probably bought to make money on these? Do you know that today's 1 generation AAV gene therapy, which will be outcompeted, typically costs between 10 and 40 mill for a single dose? Do you know that today's ex vivo (outside the body) cell therapy CAR-T costs a total of 10 - 20 mill and the medicine alone costs approx 4 mill kroner?? Circio with circVec seems to have the potential to become a key component in 2 generation AAV gene therapy and possibly in in vivo CAR-T cell therapy against cancer and autoimmune diseases. Enormous patient bases. Millions of people can gain access to the new generation treatment with AAV and CAR-T in vivo. That is the potential. Big pharma acquires promising technologies and platforms in 2 generation in preclinical phase for billions. Because they see an enormous revenue potential in these treatment forms that can become easily accessible and much cheaper. Take an example just to play with numbers: A treatment in 2 generation AAV and CAR-T will in the future cost kr. 600,000. The income is distributed among 3 elements: 1) On the medicine/active substance itself 2) On the vector product - AAV / LNP et al. 3) On the expression system - circVec 1/3 part of 600,000 for each patient to Circio for use/license of CircVec. That is Kr. 200,000. So let's say that products with circVec are only delivered to 1 mill patients per year in all these medical areas. Circio's earnings will then be 200 billion per year. Cost for production of circVec and development is theoretically set to half Mcap will then possibly be 100 billion x 20? = 2000 billion With 300 mill shares after today's share issue, you can calculate the share price potential yourself. It's about money. I know you're thinking - GreatReset has gone bananas today. This is written for you to think about finances, not because the calculation is correct. Big Pharma can calculate - Pareto probably also calculates these days - but all other analysts don't calculate. You who buy shares today are early. And the shareholders here on Nordnet wonder if they should subscribe to the share issue or buy shares for 8.25 and sell for 9.50??? Everything boils down to money. Time to start thinking about what might be behind 50X, 40X, CAR-T that is coming soon.·7 min sitten · Muokattu… as Lubor Gaal says, the value of Circio can be enormous.
·45 min sittenI had TR until yesterday, wanted to redeem fissecivdag, but now they are zeroed out in VPS? Can someone explain to me? I thought I redeemed 1000 yesterday, wanted to test, but now I only see that my 18000 TR are zeroed out?
·2 t sittenRaise your hand those who always manage to buy shares at the bottom. And raise your hand those who always read and analyze what is continuously published of news, updates, interviews, strategies and goal achievement directly from the management in Circio. Especially the last week the forum has been obsessed with the issue price of kr 8,2508, who/what controls the price development and the fear of paying ten øre too much for the share upon redemption of TR. The big picture is blurred by a short-term focus on details and disturbs some people's ability to think long-term. The small, but important signals the management sends out in words and actions unfortunately lose their meaning. You who bought the share yesterday for kr 8,17 run the same risk as me, who today will redeem my TR for kr 8,2508/8,2707 - with the intention of increasing my percentage share in the company. For me, this is worth 8-10 øre extra. I am prepared for the price to go down further for a period when the shares come onto the market. In that case, it will affect everyone with shares in the company. The risk is the same, we are in the same boat. And you who do not have shares, but write so furiously here on the forum, also run a risk, you admittedly have nothing to lose, but also nothing to gain. Feel free to call me a naive idiot who redeems TR at a higher price, I don't care. What guides my choices and my risk assessment is solely and exclusively the belief in circVec technology and the knowledge of what the company itself writes in its presentation that they stand for. So far, Wiklund&Co has kept what they promised and had a goal achievement far beyond expectation. Ergo, the trust in the management has been strengthened from the day I became a shareholder via the issue at kr 1. Previously I have contributed funds to research in Kreftforeningen. This year I redeem TR in Circio and contribute to Circio's research. Loyal idiot, well then. As a shareholder, it benefits me that the company is best equipped to succeed. For me, this is a long-term strategy and the key to potential success. Ridicule on the forum about idiots who redeem TR despite today's price level doesn't affect me, so we'll see who laughs last. For he who laughs last always laughs best.
·34 min sittenAmen, I agree with everything. It's also a given for me to contribute. If the stock had been at 7 kronor, I would still have subscribed at least as much as the management did. I am convinced that cash will be used well. I think they have so far fulfilled what they promised and more = highest confidence in our Dreamteam. If the stock drops in the coming weeks, I will buy more and see it as having lowered my ACB on the rights issue. The cash has been prepared for several weeks. Good post Oppogner!
·19 min sittenProbably difficult for you to understand, Baretap12. But for many of us, it provides extra motivation to invest in a company that has the potential to change public health. We think long-term, have trust (understand that's a foreign word to you) and are a bit naive with pride. Go go, Circio.- ·4 t sitten · MuokattuTHIS YEAR'S HOTTEST EMISSION No, it's not SpaceX. It's Circio, Oslo Børs's own bio rocket. June 9, 2026 is the last day to subscribe for shares in what will be the company's last emission at a market price of around 2 billion. A technology company with with a platform that has a universal function and effect in most organs and tissues in the body. Thus, the potential is that circVec becomes a core technology that must be included in a number of treatments in gene and cell therapy. It is unlikely that there will be an opportunity in the future to become a co-owner and shareholder in a Nordic company with such potential at such an early stage. Financial risk is gone and the technology has been increasingly validated in its own studies and by partners. This year's stock market winner. Personal price target - a three-bagger until September.
·1 t sittenI have already set aside money for the next issue. - ·8 t sitten · MuokattuThe cost per share for those who exercise warrants is. Strike 8.25 + cost tr. What we know is that many have had a cost per warrant of 0.4-0.5 Then we get a real cost for (a good portion) to exercise warrants. 8.65-8.75 kr per new share. Then it is quite incredible to see today's price at 8.17.
·3 t sittenI have no warrants but am heavily invested here. I have faith even though I have an average price GAD of 9.45.! (Big loss so far, in other words) Chat GPT can be said a lot about, but I use it like everyone else. Useful tool. Attaching an answer that might/should be of interest and a "lively" discussion for insight!? lileljohn1/Djesnes. Do you have any answer to the last paragraph regarding who, prospectus, agreement, fee, shares or derivatives for the guarantors? My question: Who are the "guarantors" and how does it work? Can they short and make the price further volatile and unstable? Answer: Yes, that is a relevant question, because guarantors can influence the market indirectly, but how they do it depends on the issue agreement. Who are the guarantors? In an issue or warrant round, certain investors guarantee that the company will raise the capital. Example: * Circio wants to raise 100 million. * Existing shareholders receive TR/warrants. * The guarantors promise to buy what is not subscribed. If only 70 million is subscribed, the guarantors must take the last 30 million. In return, they normally receive: * A guarantee fee (often in shares or warrants). * Opportunity to buy shares on the issue terms. ⸻ Why might they want a low price? If the guarantors end up with many shares at 8.25 kr, it can be favorable if few others exercise their right. The fewer who subscribe: * the more shares accrue to the guarantors. * the larger ownership stake they can get. This is what Djensen refers to. ⸻ Can they short? Yes, in theory. A common strategy among professional investors in issues is: 1. They know they will probably get shares at 8.25. 2. They short the share in the market at higher levels. 3. When the issue shares are delivered, they cover the short with the new shares. This is often called a “hedge”. Example: * Short sale at 8.80 kr. * Receives issue shares at 8.25 kr. * Profit 0.55 kr per share. This is not necessarily illegal if it happens within the regulations. ⸻ Can this create pressure and volatility? Absolutely. If several guarantors or arbitrage funds do this simultaneously:
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
55 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·13 min sittenThere is no one discussing economics in the Circio share? Here, circVec's results from the study programs are being discussed - 50-60X better effect in Eye, 40X in heart, x x in CNC, potential muscles, lungs, kidneys, low toxicity, specific delivery etc, partners etc. We are waiting for CAR-T shortly. Shares are probably bought to make money on these? Do you know that today's 1 generation AAV gene therapy, which will be outcompeted, typically costs between 10 and 40 mill for a single dose? Do you know that today's ex vivo (outside the body) cell therapy CAR-T costs a total of 10 - 20 mill and the medicine alone costs approx 4 mill kroner?? Circio with circVec seems to have the potential to become a key component in 2 generation AAV gene therapy and possibly in in vivo CAR-T cell therapy against cancer and autoimmune diseases. Enormous patient bases. Millions of people can gain access to the new generation treatment with AAV and CAR-T in vivo. That is the potential. Big pharma acquires promising technologies and platforms in 2 generation in preclinical phase for billions. Because they see an enormous revenue potential in these treatment forms that can become easily accessible and much cheaper. Take an example just to play with numbers: A treatment in 2 generation AAV and CAR-T will in the future cost kr. 600,000. The income is distributed among 3 elements: 1) On the medicine/active substance itself 2) On the vector product - AAV / LNP et al. 3) On the expression system - circVec 1/3 part of 600,000 for each patient to Circio for use/license of CircVec. That is Kr. 200,000. So let's say that products with circVec are only delivered to 1 mill patients per year in all these medical areas. Circio's earnings will then be 200 billion per year. Cost for production of circVec and development is theoretically set to half Mcap will then possibly be 100 billion x 20? = 2000 billion With 300 mill shares after today's share issue, you can calculate the share price potential yourself. It's about money. I know you're thinking - GreatReset has gone bananas today. This is written for you to think about finances, not because the calculation is correct. Big Pharma can calculate - Pareto probably also calculates these days - but all other analysts don't calculate. You who buy shares today are early. And the shareholders here on Nordnet wonder if they should subscribe to the share issue or buy shares for 8.25 and sell for 9.50??? Everything boils down to money. Time to start thinking about what might be behind 50X, 40X, CAR-T that is coming soon.·7 min sitten · Muokattu… as Lubor Gaal says, the value of Circio can be enormous.
- ·45 min sittenI had TR until yesterday, wanted to redeem fissecivdag, but now they are zeroed out in VPS? Can someone explain to me? I thought I redeemed 1000 yesterday, wanted to test, but now I only see that my 18000 TR are zeroed out?
- ·2 t sittenRaise your hand those who always manage to buy shares at the bottom. And raise your hand those who always read and analyze what is continuously published of news, updates, interviews, strategies and goal achievement directly from the management in Circio. Especially the last week the forum has been obsessed with the issue price of kr 8,2508, who/what controls the price development and the fear of paying ten øre too much for the share upon redemption of TR. The big picture is blurred by a short-term focus on details and disturbs some people's ability to think long-term. The small, but important signals the management sends out in words and actions unfortunately lose their meaning. You who bought the share yesterday for kr 8,17 run the same risk as me, who today will redeem my TR for kr 8,2508/8,2707 - with the intention of increasing my percentage share in the company. For me, this is worth 8-10 øre extra. I am prepared for the price to go down further for a period when the shares come onto the market. In that case, it will affect everyone with shares in the company. The risk is the same, we are in the same boat. And you who do not have shares, but write so furiously here on the forum, also run a risk, you admittedly have nothing to lose, but also nothing to gain. Feel free to call me a naive idiot who redeems TR at a higher price, I don't care. What guides my choices and my risk assessment is solely and exclusively the belief in circVec technology and the knowledge of what the company itself writes in its presentation that they stand for. So far, Wiklund&Co has kept what they promised and had a goal achievement far beyond expectation. Ergo, the trust in the management has been strengthened from the day I became a shareholder via the issue at kr 1. Previously I have contributed funds to research in Kreftforeningen. This year I redeem TR in Circio and contribute to Circio's research. Loyal idiot, well then. As a shareholder, it benefits me that the company is best equipped to succeed. For me, this is a long-term strategy and the key to potential success. Ridicule on the forum about idiots who redeem TR despite today's price level doesn't affect me, so we'll see who laughs last. For he who laughs last always laughs best.·34 min sittenAmen, I agree with everything. It's also a given for me to contribute. If the stock had been at 7 kronor, I would still have subscribed at least as much as the management did. I am convinced that cash will be used well. I think they have so far fulfilled what they promised and more = highest confidence in our Dreamteam. If the stock drops in the coming weeks, I will buy more and see it as having lowered my ACB on the rights issue. The cash has been prepared for several weeks. Good post Oppogner!·19 min sittenProbably difficult for you to understand, Baretap12. But for many of us, it provides extra motivation to invest in a company that has the potential to change public health. We think long-term, have trust (understand that's a foreign word to you) and are a bit naive with pride. Go go, Circio.
- ·4 t sitten · MuokattuTHIS YEAR'S HOTTEST EMISSION No, it's not SpaceX. It's Circio, Oslo Børs's own bio rocket. June 9, 2026 is the last day to subscribe for shares in what will be the company's last emission at a market price of around 2 billion. A technology company with with a platform that has a universal function and effect in most organs and tissues in the body. Thus, the potential is that circVec becomes a core technology that must be included in a number of treatments in gene and cell therapy. It is unlikely that there will be an opportunity in the future to become a co-owner and shareholder in a Nordic company with such potential at such an early stage. Financial risk is gone and the technology has been increasingly validated in its own studies and by partners. This year's stock market winner. Personal price target - a three-bagger until September.·1 t sittenI have already set aside money for the next issue.
- ·8 t sitten · MuokattuThe cost per share for those who exercise warrants is. Strike 8.25 + cost tr. What we know is that many have had a cost per warrant of 0.4-0.5 Then we get a real cost for (a good portion) to exercise warrants. 8.65-8.75 kr per new share. Then it is quite incredible to see today's price at 8.17.·3 t sittenI have no warrants but am heavily invested here. I have faith even though I have an average price GAD of 9.45.! (Big loss so far, in other words) Chat GPT can be said a lot about, but I use it like everyone else. Useful tool. Attaching an answer that might/should be of interest and a "lively" discussion for insight!? lileljohn1/Djesnes. Do you have any answer to the last paragraph regarding who, prospectus, agreement, fee, shares or derivatives for the guarantors? My question: Who are the "guarantors" and how does it work? Can they short and make the price further volatile and unstable? Answer: Yes, that is a relevant question, because guarantors can influence the market indirectly, but how they do it depends on the issue agreement. Who are the guarantors? In an issue or warrant round, certain investors guarantee that the company will raise the capital. Example: * Circio wants to raise 100 million. * Existing shareholders receive TR/warrants. * The guarantors promise to buy what is not subscribed. If only 70 million is subscribed, the guarantors must take the last 30 million. In return, they normally receive: * A guarantee fee (often in shares or warrants). * Opportunity to buy shares on the issue terms. ⸻ Why might they want a low price? If the guarantors end up with many shares at 8.25 kr, it can be favorable if few others exercise their right. The fewer who subscribe: * the more shares accrue to the guarantors. * the larger ownership stake they can get. This is what Djensen refers to. ⸻ Can they short? Yes, in theory. A common strategy among professional investors in issues is: 1. They know they will probably get shares at 8.25. 2. They short the share in the market at higher levels. 3. When the issue shares are delivered, they cover the short with the new shares. This is often called a “hedge”. Example: * Short sale at 8.80 kr. * Receives issue shares at 8.25 kr. * Profit 0.55 kr per share. This is not necessarily illegal if it happens within the regulations. ⸻ Can this create pressure and volatility? Absolutely. If several guarantors or arbitrage funds do this simultaneously:
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 365 | - | - | ||
| 85 | - | - | ||
| 5 000 | - | - | ||
| 10 000 | - | - | ||
| 46 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
55 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·13 min sittenThere is no one discussing economics in the Circio share? Here, circVec's results from the study programs are being discussed - 50-60X better effect in Eye, 40X in heart, x x in CNC, potential muscles, lungs, kidneys, low toxicity, specific delivery etc, partners etc. We are waiting for CAR-T shortly. Shares are probably bought to make money on these? Do you know that today's 1 generation AAV gene therapy, which will be outcompeted, typically costs between 10 and 40 mill for a single dose? Do you know that today's ex vivo (outside the body) cell therapy CAR-T costs a total of 10 - 20 mill and the medicine alone costs approx 4 mill kroner?? Circio with circVec seems to have the potential to become a key component in 2 generation AAV gene therapy and possibly in in vivo CAR-T cell therapy against cancer and autoimmune diseases. Enormous patient bases. Millions of people can gain access to the new generation treatment with AAV and CAR-T in vivo. That is the potential. Big pharma acquires promising technologies and platforms in 2 generation in preclinical phase for billions. Because they see an enormous revenue potential in these treatment forms that can become easily accessible and much cheaper. Take an example just to play with numbers: A treatment in 2 generation AAV and CAR-T will in the future cost kr. 600,000. The income is distributed among 3 elements: 1) On the medicine/active substance itself 2) On the vector product - AAV / LNP et al. 3) On the expression system - circVec 1/3 part of 600,000 for each patient to Circio for use/license of CircVec. That is Kr. 200,000. So let's say that products with circVec are only delivered to 1 mill patients per year in all these medical areas. Circio's earnings will then be 200 billion per year. Cost for production of circVec and development is theoretically set to half Mcap will then possibly be 100 billion x 20? = 2000 billion With 300 mill shares after today's share issue, you can calculate the share price potential yourself. It's about money. I know you're thinking - GreatReset has gone bananas today. This is written for you to think about finances, not because the calculation is correct. Big Pharma can calculate - Pareto probably also calculates these days - but all other analysts don't calculate. You who buy shares today are early. And the shareholders here on Nordnet wonder if they should subscribe to the share issue or buy shares for 8.25 and sell for 9.50??? Everything boils down to money. Time to start thinking about what might be behind 50X, 40X, CAR-T that is coming soon.·7 min sitten · Muokattu… as Lubor Gaal says, the value of Circio can be enormous.
- ·45 min sittenI had TR until yesterday, wanted to redeem fissecivdag, but now they are zeroed out in VPS? Can someone explain to me? I thought I redeemed 1000 yesterday, wanted to test, but now I only see that my 18000 TR are zeroed out?
- ·2 t sittenRaise your hand those who always manage to buy shares at the bottom. And raise your hand those who always read and analyze what is continuously published of news, updates, interviews, strategies and goal achievement directly from the management in Circio. Especially the last week the forum has been obsessed with the issue price of kr 8,2508, who/what controls the price development and the fear of paying ten øre too much for the share upon redemption of TR. The big picture is blurred by a short-term focus on details and disturbs some people's ability to think long-term. The small, but important signals the management sends out in words and actions unfortunately lose their meaning. You who bought the share yesterday for kr 8,17 run the same risk as me, who today will redeem my TR for kr 8,2508/8,2707 - with the intention of increasing my percentage share in the company. For me, this is worth 8-10 øre extra. I am prepared for the price to go down further for a period when the shares come onto the market. In that case, it will affect everyone with shares in the company. The risk is the same, we are in the same boat. And you who do not have shares, but write so furiously here on the forum, also run a risk, you admittedly have nothing to lose, but also nothing to gain. Feel free to call me a naive idiot who redeems TR at a higher price, I don't care. What guides my choices and my risk assessment is solely and exclusively the belief in circVec technology and the knowledge of what the company itself writes in its presentation that they stand for. So far, Wiklund&Co has kept what they promised and had a goal achievement far beyond expectation. Ergo, the trust in the management has been strengthened from the day I became a shareholder via the issue at kr 1. Previously I have contributed funds to research in Kreftforeningen. This year I redeem TR in Circio and contribute to Circio's research. Loyal idiot, well then. As a shareholder, it benefits me that the company is best equipped to succeed. For me, this is a long-term strategy and the key to potential success. Ridicule on the forum about idiots who redeem TR despite today's price level doesn't affect me, so we'll see who laughs last. For he who laughs last always laughs best.·34 min sittenAmen, I agree with everything. It's also a given for me to contribute. If the stock had been at 7 kronor, I would still have subscribed at least as much as the management did. I am convinced that cash will be used well. I think they have so far fulfilled what they promised and more = highest confidence in our Dreamteam. If the stock drops in the coming weeks, I will buy more and see it as having lowered my ACB on the rights issue. The cash has been prepared for several weeks. Good post Oppogner!·19 min sittenProbably difficult for you to understand, Baretap12. But for many of us, it provides extra motivation to invest in a company that has the potential to change public health. We think long-term, have trust (understand that's a foreign word to you) and are a bit naive with pride. Go go, Circio.
- ·4 t sitten · MuokattuTHIS YEAR'S HOTTEST EMISSION No, it's not SpaceX. It's Circio, Oslo Børs's own bio rocket. June 9, 2026 is the last day to subscribe for shares in what will be the company's last emission at a market price of around 2 billion. A technology company with with a platform that has a universal function and effect in most organs and tissues in the body. Thus, the potential is that circVec becomes a core technology that must be included in a number of treatments in gene and cell therapy. It is unlikely that there will be an opportunity in the future to become a co-owner and shareholder in a Nordic company with such potential at such an early stage. Financial risk is gone and the technology has been increasingly validated in its own studies and by partners. This year's stock market winner. Personal price target - a three-bagger until September.·1 t sittenI have already set aside money for the next issue.
- ·8 t sitten · MuokattuThe cost per share for those who exercise warrants is. Strike 8.25 + cost tr. What we know is that many have had a cost per warrant of 0.4-0.5 Then we get a real cost for (a good portion) to exercise warrants. 8.65-8.75 kr per new share. Then it is quite incredible to see today's price at 8.17.·3 t sittenI have no warrants but am heavily invested here. I have faith even though I have an average price GAD of 9.45.! (Big loss so far, in other words) Chat GPT can be said a lot about, but I use it like everyone else. Useful tool. Attaching an answer that might/should be of interest and a "lively" discussion for insight!? lileljohn1/Djesnes. Do you have any answer to the last paragraph regarding who, prospectus, agreement, fee, shares or derivatives for the guarantors? My question: Who are the "guarantors" and how does it work? Can they short and make the price further volatile and unstable? Answer: Yes, that is a relevant question, because guarantors can influence the market indirectly, but how they do it depends on the issue agreement. Who are the guarantors? In an issue or warrant round, certain investors guarantee that the company will raise the capital. Example: * Circio wants to raise 100 million. * Existing shareholders receive TR/warrants. * The guarantors promise to buy what is not subscribed. If only 70 million is subscribed, the guarantors must take the last 30 million. In return, they normally receive: * A guarantee fee (often in shares or warrants). * Opportunity to buy shares on the issue terms. ⸻ Why might they want a low price? If the guarantors end up with many shares at 8.25 kr, it can be favorable if few others exercise their right. The fewer who subscribe: * the more shares accrue to the guarantors. * the larger ownership stake they can get. This is what Djensen refers to. ⸻ Can they short? Yes, in theory. A common strategy among professional investors in issues is: 1. They know they will probably get shares at 8.25. 2. They short the share in the market at higher levels. 3. When the issue shares are delivered, they cover the short with the new shares. This is often called a “hedge”. Example: * Short sale at 8.80 kr. * Receives issue shares at 8.25 kr. * Profit 0.55 kr per share. This is not necessarily illegal if it happens within the regulations. ⸻ Can this create pressure and volatility? Absolutely. If several guarantors or arbitrage funds do this simultaneously:
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 365 | - | - | ||
| 85 | - | - | ||
| 5 000 | - | - | ||
| 10 000 | - | - | ||
| 46 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt